MIRA Pharmaceuticals Announces Promising Topline Results from Phase 1 Study of Novel Oral Therapeutic Ketamir-2

Reuters

2025/09/22

MIRA Pharmaceuticals Announces Promising Topline Results from Phase 1 Study of Novel Oral Therapeutic Ketamir-2

MIRA Pharmaceuticals, Inc. $(MIRA)$ has announced topline results from the single ascending dose portion of its Phase 1 clinical trial for its lead oral candidate, Ketamir-2. The study evaluated the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. Conducted in a randomized, placebo-controlled format, the trial involved 32 participants across four escalating dose cohorts. Key findings indicate that Ketamir-2 was safe and well tolerated across all dose levels, with no severe adverse effects observed. The drug exhibited rapid and predictable absorption, supporting once-daily dosing, and did not present the CNS side effects commonly associated with ketamine. These results, already presented, highlight Ketamir-2's potential as a non-addictive treatment option for neuropathic pain, with the company exploring strategic partnerships to advance its development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1076223) on September 22, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569781067"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569781067\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569781067?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569781067","market":"nz","top_or_hot":-1,"title":"MIRA Pharmaceuticals Announces Promising Topline Results from Phase 1 Study of Novel Oral Therapeutic Ketamir-2","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MIRA Pharmaceuticals Announces Promising Topline Results from Phase 1 Study of Novel Oral Therapeutic Ketamir-2\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MIRA Pharmaceuticals, Inc. <a href=\"https://laohu8.com/S/MIRA\">$(MIRA)$</a> has announced topline results from the single ascending dose portion of its Phase 1 clinical trial for its lead oral candidate, Ketamir-2. The study evaluated the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. Conducted in a randomized, placebo-controlled format, the trial involved 32 participants across four escalating dose cohorts. Key findings indicate that Ketamir-2 was safe and well tolerated across all dose levels, with no severe adverse effects observed. The drug exhibited rapid and predictable absorption, supporting once-daily dosing, and did not present the CNS side effects commonly associated with ketamine. These results, already presented, highlight Ketamir-2's potential as a non-addictive treatment option for neuropathic pain, with the company exploring strategic partnerships to advance its development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1076223) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MIRA Pharmaceuticals Announces Promising Topline Results from Phase 1 Study of Novel Oral Therapeutic Ketamir-2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMIRA Pharmaceuticals Announces Promising Topline Results from Phase 1 Study of Novel Oral Therapeutic Ketamir-2\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-22 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MIRA Pharmaceuticals Announces Promising Topline Results from Phase 1 Study of Novel Oral Therapeutic Ketamir-2\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MIRA Pharmaceuticals, Inc. <a href=\"https://laohu8.com/S/MIRA\">$(MIRA)$</a> has announced topline results from the single ascending dose portion of its Phase 1 clinical trial for its lead oral candidate, Ketamir-2. The study evaluated the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. Conducted in a randomized, placebo-controlled format, the trial involved 32 participants across four escalating dose cohorts. Key findings indicate that Ketamir-2 was safe and well tolerated across all dose levels, with no severe adverse effects observed. The drug exhibited rapid and predictable absorption, supporting once-daily dosing, and did not present the CNS side effects commonly associated with ketamine. These results, already presented, highlight Ketamir-2's potential as a non-addictive treatment option for neuropathic pain, with the company exploring strategic partnerships to advance its development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1076223) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL63NvBq:1","article_id":"2569781067","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569781067","pubTimestamp":1758542445,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MIRA Pharmaceuticals, Inc.  has announced topline results from the single ascending dose portion of its Phase 1 clinical trial for its lead oral candidate, Ketamir-2. The study evaluated the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. Conducted in a randomized, placebo-controlled format, the trial involved 32 participants across four escalating dose cohorts. Key findings indicate that Ketamir-2 was safe and well tolerated across all dose levels, with no severe adverse effects observed. The drug exhibited rapid and predictable absorption, supporting once-daily dosing, and did not present the CNS side effects commonly associated with ketamine. These results, already presented, highlight Ketamir-2's potential as a non-addictive treatment option for neuropathic pain, with the company exploring strategic partnerships to advance its development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUB","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","MIRA":"Mira Pharma"},"translate_title":"MIRA Pharmaceuticals宣布新型口服治疗药物Ketamir-2的1期研究结果令人鼓舞","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRA":0.9},"content_text":"MIRA Pharmaceuticals Announces Promising Topline Results from Phase 1 Study of Novel Oral Therapeutic Ketamir-2\n    \n\n        MIRA Pharmaceuticals, Inc. $(MIRA)$ has announced topline results from the single ascending dose portion of its Phase 1 clinical trial for its lead oral candidate, Ketamir-2. The study evaluated the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. Conducted in a randomized, placebo-controlled format, the trial involved 32 participants across four escalating dose cohorts. Key findings indicate that Ketamir-2 was safe and well tolerated across all dose levels, with no severe adverse effects observed. The drug exhibited rapid and predictable absorption, supporting once-daily dosing, and did not present the CNS side effects commonly associated with ketamine. These results, already presented, highlight Ketamir-2's potential as a non-addictive treatment option for neuropathic pain, with the company exploring strategic partnerships to advance its development.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1076223) on September 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}